Creates grant program in DOH to increase early detection of and intervention for uterine fibroids; appropriates $5 million.
Summary
This bill creates a Department of Health grant program focused on improving the early detection of, and intervention for, uterine fibroids. The program would fund organizations that conduct research, run public awareness campaigns, provide screening and patient navigation services, and implement evidence-based strategies to improve diagnosis and treatment. It also allows funding for related research on pain management disparities in uterine fibroid surgery and on other intrauterine conditions, including Asherman's syndrome and intrauterine adhesions.
The bill requires the Commissioner of Health to establish an application process, set reporting requirements for grant recipients, and develop evidence-based strategies and training materials for health care providers based on the research funded by the program. Grant recipients must track screening rates, early diagnosis rates, late-stage complications, and patient outcomes, and the commissioner must report annually to the Governor and Legislature on grant awards and recipient reports. The bill also directs the commissioner, in consultation with the Commissioner of Banking and Insurance, to recommend policies within one year to help ensure coverage for uterine fibroid screening and treatment under state-regulated health plans.
Impact
The bill would add a new state program within the Department of Health and create a nonlapsing, revolving Uterine Fibroids Prevention Fund in the Department of the Treasury to support grants related to uterine fibroid research, screening, and intervention. It appropriates $5 million from the General Fund to seed the fund and authorizes the fund to receive state, federal, and private money. It also directs the Department of Health and the Department of Banking and Insurance to evaluate insurance coverage policy options for uterine fibroid screening and treatment, potentially affecting state-regulated health plans and future coverage standards.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive and public-health oriented. The measure is framed as a targeted effort to address a specific women’s health condition through research, outreach, screening, and provider education, with an emphasis on measurable outcomes and community partnerships. No formal opposition, amendments, or recorded vote concerns are included in the available context.
Contention
The main policy issues raised by the bill itself are not partisan but operational and fiscal: how the $5 million appropriation will be allocated, which organizations will qualify for grants, and how the Department of Health will define and prioritize evidence-based strategies and community-based partnerships. Another possible point of contention is the bill’s direction to evaluate insurance coverage for screening and treatment, which could have implications for regulated health plans and future mandates. The bill also expands the scope of funded research beyond uterine fibroids to related conditions such as Asherman's syndrome and intrauterine adhesions, which may raise questions about program focus and breadth.